The FDA has approved Eli Lilly's Alzheimer's drug, donanemab, under the brand name Kisunla, for adults with early symptomatic Alzheimer's disease. With nearly 7 million Americans currently suffering from this mind-wasting disease and projections showing this number could nearly double by 2050, this approval marks a significant milestone in the treatment of Alzheimer's. Donanemab will compete with a similar treatment from Biogen and Eisai called Leqembi, both of which target toxic plaques in the brain to slow disease progression. In clinical trials, Eli Lilly's drug showed a 35% reduction in disease progression compared to a placebo. This approval comes after setbacks and delays last year, making it a long-awaited win for Eli Lilly and providing new hope for those affected by Alzheimer's.